A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms

Inclusion Criteria:

1. Patient is at least 18 years old

2. Patient plans to undergo surgical resection of a cutaneous neoplasm

3. Patient is willing and capable of complying with all protocol requirements

4. Patient or legally authorized representative (LAR) is willing to provide writteninformed consent prior to participation in study

5. Post-resection surgical wound with a surface area of ≥4 cm2 and ≤ 36cm2

Exclusion Criteria:

1. Inability to give informed consent or to complete the procedures required for studycompletion

2. Patient has been previously enrolled into this study, or is currently participatingin another drug or device study that has not reached its primary endpoint

3. Patient is pregnant, breast feeding or planning to become pregnant

4. Patient has a known allergy to resorbable suture materials, e.g. Polyglactin 910 (PGLA), Polydioxanone (PDS)

5. Patients receiving any immunotherapy, radiation, or chemotherapy within the pastfour weeks prior to resection surgery.

6. Patient has a life expectancy less than six months as assessed by the investigator

7. Patient has an additional non-study related wound within 3 cm of the study wound

8. Study wound is located on the hands or feet

9. Patient has been diagnosed with osteomalacia

10. Resection defect from a squamous cell carcinoma arising from a chronic wound

11. Patient has an uncontrolled thyroid disorder

12. Hgb A1c > 12% within 3 months prior to enrollment in patients with a known historyof diabetes

13. Patient has a BMI > 34.9

14. Patient has used any tobacco product within the past 30 days prior to surgery

15. Patients with chronic kidney disease on peritoneal or hemodialysis, or with anestimated glomerular filtration rate less than 15mL/min

16. Patients with severe liver disease with active cirrhosis defined as a gross ascitesupon clinical exam or a Model for End-stage Liver Disease (MELD)-Na score greaterthan 15

17. Patient not in reasonable metabolic control in the judgement of the investigator

18. Patient has a known history of poor compliance with medical treatment

19. Patient has a history of radiotherapy to wound bed of interest

20. Patient has been diagnosed with at least one of the following autoimmune connectivetissue diseases: lupus, vasculitis, sickle cell, or uncontrolled rheumatoidarthritis

21. Active infection, undrained abscess, or critical colonization of the wound withbacteria in the judgement of the investigator